Related Experiment Video

Updated: Sep 6, 2025

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.0K

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma

Jessica Davis1, Megan Wayman2

  • 1Levine Cancer Institute, Charlotte, North Carolina.

Journal of the Advanced Practitioner in Oncology
|June 27, 2022
PubMed

Insights

New B-Raf and MEK inhibitor combinations, like encorafenib plus binimetinib, offer improved survival for metastatic melanoma patients with BRAF mutations. These targeted therapies represent significant advancements in cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Metastatic melanoma treatment has evolved with targeted therapies.
  • BRAF V600E/K mutations are key drivers in a subset of melanoma patients.
  • Previous treatments showed limited efficacy in advanced melanoma.

Purpose of the Study:

  • To evaluate the efficacy of encorafenib plus binimetinib versus vemurafenib in metastatic melanoma.
  • To compare progression-free survival (PFS) and overall survival (OS) between treatment arms.
  • To inform clinical decision-making for BRAF-mutated melanoma.

Main Methods:

  • The COLUMBUS trial investigated the combination of encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor).
  • Patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations were included.
  • Outcomes were compared against vemurafenib monotherapy.

Main Results:

  • The combination of encorafenib plus binimetinib demonstrated improved progression-free survival compared to vemurafenib alone.
  • Overall survival was also improved with the combination regimen.
  • Encorafenib plus binimetinib is a significant advancement as a third approved BRAF plus MEK inhibitor combination.

Conclusions:

  • Encorafenib plus binimetinib is an effective treatment option for patients with BRAF-mutated metastatic melanoma.
  • The study highlights the benefits of combination targeted therapy in improving patient outcomes.
  • Clinical and practical differences between BRAF plus MEK inhibitor combinations warrant careful consideration for treatment selection.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.5K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K